Dual action

Lybrido stimulates the dual action

We found that administering a small dose of testosterone in a specific pharmacological formulation has a positive effect on both genital and subjective sexual arousal in healthy female volunteers. As with the use of PDE5 Inhibitors this form of testosterone administration is not sufficient for the treatment of FSD.

This line of reasoning led to the development of Lybrido: a combination of testosterone and a PDE5 Inhibitor. This medicine influences brain mechanisms involved in sexual motivation as well as the physical genital sexual response. This crucial combination creates a synergistic effect. The testosterone ensures greater attention for sexual cues and an increase in sexual motivation; the PDE 5inhibitors causes a faster, greater and more protracted vaginal arousal.